Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy requiring urgent treatment advancements. Ceramide is a cell-death-promoting signaling lipid that plays a central role in therapy-induced cell death. We previously determined that acid ceramidase (AC), a ceramide-depleting enzyme, is overexpressed in AML and promotes leukemic survival and drug resistance. The ceramidase inhibitor B-13 and next-generation lysosomal-localizing derivatives termed dimethylglycine (DMG)-B-13 prodrugs have been developed but remain untested in AML. Here, we report the in vitro anti-leukemic efficacy and mechanism of DMG-B-13 prodrug LCL-805 across AML cell lines and primary patient samples. LCL-805 inhibited AC enzymatic activity, increased total ceramides, and reduced sphingosine levels. A median EC50 value of 11.7 μM was achieved for LCL-805 in cell viability assays across 32 human AML cell lines. As a single agent tested across a panel of 71 primary AML patient samples, a median EC50 value of 15.8 μM was achieved. Exogenous ceramide supplementation with C6-ceramide nanoliposomes, which is entering phase I/II clinical trial for relapsed/refractory AML, significantly enhanced LCL-805 killing. Mechanistically, LCL-805 antagonized Akt signaling and led to iron-dependent cell death distinct from canonical ferroptosis. These findings elucidated key factors involved in LCL-805 cytotoxicity and demonstrated the potency of combining AC inhibition with exogenous ceramide.
Errataetall: | |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
---|---|
Enthalten in: |
Cancers - 15(2023), 24 vom: 15. Dez. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ung, Johnson [VerfasserIn] |
---|
Links: |
---|
Themen: |
Acid ceramidase |
---|
Anmerkungen: |
Date Revised 10.04.2024 published: Electronic UpdateOf: bioRxiv. 2023 Oct 23;:. - PMID 37961314 Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/cancers15245866 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM366270737 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM366270737 | ||
003 | DE-627 | ||
005 | 20240410232344.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231227s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/cancers15245866 |2 doi | |
028 | 5 | 2 | |a pubmed24n1371.xml |
035 | |a (DE-627)NLM366270737 | ||
035 | |a (NLM)38136410 | ||
035 | |a (PII)5866 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ung, Johnson |e verfasserin |4 aut | |
245 | 1 | 0 | |a Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 10.04.2024 | ||
500 | |a published: Electronic | ||
500 | |a UpdateOf: bioRxiv. 2023 Oct 23;:. - PMID 37961314 | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Acute myeloid leukemia (AML) is an aggressive hematologic malignancy requiring urgent treatment advancements. Ceramide is a cell-death-promoting signaling lipid that plays a central role in therapy-induced cell death. We previously determined that acid ceramidase (AC), a ceramide-depleting enzyme, is overexpressed in AML and promotes leukemic survival and drug resistance. The ceramidase inhibitor B-13 and next-generation lysosomal-localizing derivatives termed dimethylglycine (DMG)-B-13 prodrugs have been developed but remain untested in AML. Here, we report the in vitro anti-leukemic efficacy and mechanism of DMG-B-13 prodrug LCL-805 across AML cell lines and primary patient samples. LCL-805 inhibited AC enzymatic activity, increased total ceramides, and reduced sphingosine levels. A median EC50 value of 11.7 μM was achieved for LCL-805 in cell viability assays across 32 human AML cell lines. As a single agent tested across a panel of 71 primary AML patient samples, a median EC50 value of 15.8 μM was achieved. Exogenous ceramide supplementation with C6-ceramide nanoliposomes, which is entering phase I/II clinical trial for relapsed/refractory AML, significantly enhanced LCL-805 killing. Mechanistically, LCL-805 antagonized Akt signaling and led to iron-dependent cell death distinct from canonical ferroptosis. These findings elucidated key factors involved in LCL-805 cytotoxicity and demonstrated the potency of combining AC inhibition with exogenous ceramide | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Akt | |
650 | 4 | |a C6-ceramide nanoliposome | |
650 | 4 | |a LCL-805 | |
650 | 4 | |a acid ceramidase | |
650 | 4 | |a acute myeloid leukemia | |
650 | 4 | |a ceramide | |
650 | 4 | |a dimethylglycine-B-13 prodrug | |
650 | 4 | |a iron chelation | |
650 | 4 | |a sphingolipids | |
700 | 1 | |a Tan, Su-Fern |e verfasserin |4 aut | |
700 | 1 | |a Fox, Todd E |e verfasserin |4 aut | |
700 | 1 | |a Shaw, Jeremy J P |e verfasserin |4 aut | |
700 | 1 | |a Taori, Maansi |e verfasserin |4 aut | |
700 | 1 | |a Horton, Bethany J |e verfasserin |4 aut | |
700 | 1 | |a Golla, Upendarrao |e verfasserin |4 aut | |
700 | 1 | |a Sharma, Arati |e verfasserin |4 aut | |
700 | 1 | |a Szulc, Zdzislaw M |e verfasserin |4 aut | |
700 | 1 | |a Wang, Hong-Gang |e verfasserin |4 aut | |
700 | 1 | |a Chalfant, Charles E |e verfasserin |4 aut | |
700 | 1 | |a Cabot, Myles C |e verfasserin |4 aut | |
700 | 1 | |a Claxton, David F |e verfasserin |4 aut | |
700 | 1 | |a Loughran, Thomas P |c Jr |e verfasserin |4 aut | |
700 | 1 | |a Feith, David J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 15(2023), 24 vom: 15. Dez. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2023 |g number:24 |g day:15 |g month:12 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers15245866 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 15 |j 2023 |e 24 |b 15 |c 12 |